Previous literature indicated that the concurrent activated KRAS and depletion of p53 could reprogram EMT-like phenotypes and increase the expression of cancer stemness genes including CD133, EpCAM, and CD24 in prostate cancer (41). This evidence concerns the gene KRAS and cancer.